Clinical Trials

Verified stories whose regulatory record supports clinical-trial access. Eligibility and enrollment are never guaranteed.

Filter clinical trials

Results

97 verified trial-access stories match your filters.

Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.

Trial Watch: Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.

InvestigationalLater-Stage Human

Cancer type: Lung Cancer
Trial identifier: NCT07279935
Trial phase: Phase 4

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Non-small Cell Lung Cancer who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-08-27

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-27

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07279935 (opens in a new tab) (Clinical-trial registry) NCT07279935 Load-bearing source NCT07279935
ClinicalTrials.gov — NCT07279935. NCT07279935.

Eligibility varies — review trial criteria.

Trial Watch: A Study Comparing BL-M07D1 With Physician’s Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan

InvestigationalLater-Stage Human

Cancer type: Colorectal Cancer
Trial identifier: NCT07730489
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants ages 18 Years to 75 Years with Colorectal Cancer who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-08-27

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-27

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07730489 (opens in a new tab) (Clinical-trial registry) NCT07730489 Load-bearing source NCT07730489
ClinicalTrials.gov — NCT07730489. NCT07730489.

Eligibility varies — review trial criteria.

Trial Watch: A Study of Xaluritamig Plus Abiraterone Versus Investigator’s Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

InvestigationalLater-Stage Human

Cancer type: Prostate Cancer
Trial identifier: NCT07213674
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Metastatic Castration-resistant Prostate Cancer who meet the study-specific registry eligibility criteria; sex eligibility: male.
Last reviewed: 2026-08-27

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-27

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07213674 (opens in a new tab) (Clinical-trial registry) NCT07213674 Load-bearing source NCT07213674
ClinicalTrials.gov — NCT07213674. NCT07213674.

Eligibility varies — review trial criteria.

Trial Watch: A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

InvestigationalLater-Stage Human

Cancer type: Leukemia, Lymphoma
Trial identifier: NCT06973187
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-08-26

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-26

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06973187 (opens in a new tab) (Clinical-trial registry) NCT06973187 Load-bearing source NCT06973187
ClinicalTrials.gov — NCT06973187. NCT06973187.

Eligibility varies — review trial criteria.

Trial Watch: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

InvestigationalLater-Stage Human

Cancer type: Pancreatic Cancer
Trial identifier: NCT03257033
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Locally Advanced Pancreatic Cancer who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-08-25

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-25

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT03257033 (opens in a new tab) (Clinical-trial registry) NCT03257033 Load-bearing source NCT03257033
ClinicalTrials.gov — NCT03257033. NCT03257033.

Eligibility varies — review trial criteria.

Trial Watch: A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

InvestigationalLater-Stage Human

Cancer type: Leukemia, Lymphoma
Trial identifier: NCT06943872
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-08-24

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-24

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06943872 (opens in a new tab) (Clinical-trial registry) NCT06943872 Load-bearing source NCT06943872
ClinicalTrials.gov — NCT06943872. NCT06943872.

Eligibility varies — review trial criteria.

Trial Watch: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

InvestigationalLater-Stage Human

Cancer type: Multiple Myeloma
Trial identifier: NCT06152575
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Multiple Myeloma who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-08-24

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-24

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06152575 (opens in a new tab) (Clinical-trial registry) NCT06152575 Load-bearing source NCT06152575
ClinicalTrials.gov — NCT06152575. NCT06152575.

Eligibility varies — review trial criteria.

Trial Watch: Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

InvestigationalLater-Stage Human

Cancer type: Breast Cancer
Trial identifier: NCT06382948
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-08-24

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-24

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06382948 (opens in a new tab) (Clinical-trial registry) NCT06382948 Load-bearing source NCT06382948
ClinicalTrials.gov — NCT06382948. NCT06382948.

Eligibility varies — review trial criteria.

Trial Watch: Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

InvestigationalLater-Stage Human

Cancer type: Prostate Cancer
Trial identifier: NCT06136624
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Prostate Cancer Metastatic who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-08-24

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-24

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06136624 (opens in a new tab) (Clinical-trial registry) NCT06136624 Load-bearing source NCT06136624
ClinicalTrials.gov — NCT06136624. NCT06136624.

Eligibility varies — review trial criteria.

Trial Watch: A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

InvestigationalLater-Stage Human

Cancer type: Prostate Cancer
Trial identifier: NCT06925737
Trial phase: Phase 3

View trial details

Study design: Other / not applicable
Population: Participants age 18 Years and older with Prostate Cancer, Prostatic Neoplasms who meet the study-specific registry eligibility criteria; sex eligibility: male.
Last reviewed: 2026-08-22

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-22

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06925737 (opens in a new tab) (Clinical-trial registry) NCT06925737 Load-bearing source NCT06925737
ClinicalTrials.gov — NCT06925737. NCT06925737.

Eligibility varies — review trial criteria.

CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.